

Joshua D. I. Ellenhorn, M.D., FACS

Personal Data

Current Address:

Surgery Group of Los Angeles
Cedars-Sinai Medical Center
8635 West Third Street
Suite 880 West
Los Angeles, CA 90048

John Wayne Cancer Clinics
2121 Santa Monica Boulevard
Santa Monica, CA 90404

Faculty Appointments:

Clinical Professor of Surgery
Cedars Sinai Medical Center
Los Angeles, California

Adjunct Professor
John Wayne Cancer Center
Santa Monica, California

Collaborative Member
Samuel Oschin Comprehensive Cancer Institute
Cedars Sinai Medical Center

Telephone:

office - 310-289-1518

Email Address:

dr@ellenhornmd.com

Date and Place of Birth:

August 16, 1960 - Torrance, California

Marital Status:

Married
Wife – Edith Ellenhorn
Children – Jacob 21, Hannah 19, Samuel 17

Medical License:

California - G 57872 - July 23, 1986

Professional Appointments

1993-2012

Staff Surgeon, City of Hope National Medical Center

1998-2010

Director of Surgical Education, City of Hope National Medical Center

2000-2012

Director - Surgical Oncology Fellowship Program
City of Hope National Medical Center

2003-2010	Associate Professor, Department of General & Oncologic Surgery City of Hope National Medical Center
2008-2012	Chief, Division of General & Oncologic Surgery, City of Hope National Medical Center
2010	Professor of Surgery City of Hope National Medical Center
2012 – present	Attending Staff Cedars Sinai Medical Center
2012 – present	Attending Staff Saint John’s Health Center, Santa Monica California
2012 – present	Collaborative Member Samuel Oschin Comprehensive Cancer Institute
2013 – present	Clinical Professor of Surgery Cedars Sinai Medical Center
2013 – present	Adjunct Professor John Wayne Cancer Center Santa Monica, California

Education and Professional Training

May 1984	B.A. - Boston University - Medical Science (Magna Cum Laude)
May 1984	M.D. - Boston University School of Medicine - (combined six-year BA/MD program)
Jul 1984 - Jun 1991	Resident - General Surgery - University of Cincinnati Hospital
Jul 1987 - Jun 1989	Post-Doctoral Research Fellow in Immunology - University of Chicago (Jeffrey A. Bluestone PhD, advisor)
Jul 1990 - Jun 1991	Chief Resident - General Surgery - University of Cincinnati Hospital

Fellowship Training

Jul 1991 - Jun 1993

Surgical Oncology Fellowship - Memorial Sloan-Kettering Cancer Center

Board Certification

1992

American Board of Surgery

2000

Recertification - American Board of Surgery

2011

Recertification - American Board of Surgery

Membership in Professional and Scientific Associations

1987

American Association for the Advancement of Science

1992 - present

Society of Surgical Oncology

1993 - 2012

Los Angeles Surgical Society(**President in 2008**)

1996 - Present

Fellow of the American College of Surgeons

1996 – Present

Member, Southern California Chapter of the American College of Surgeons

1998 - 2012

Society of Head and Neck Surgeons/American Head and Neck Society

2001 - present

Pacific Coast Surgical Association

2001 - present

American Society of Clinical Oncology

2005 - present

The Society for Surgery of the Alimentary Tract

Honors and Awards

1982

Fight for Sight Student Research Fellowship, Boston University

1987 - 1989

NIH Post-Doctoral Fellowship in Endocrinology

1990

American College of Surgeons, First Place in the Ohio State Chapter Resident Essay Contest

1992 - 1993

American Cancer Society Clinical Oncology Fellowship Award

1993

New York Society of Colon and Rectal Surgeons, First Place in the Residents Research

Presentation

1999 - 2000	Young Surgeon Representative from the Southern California Chapter to the American College of Surgeons
2005 - 2015	Listed in America's Top Doctors for Cancer, 1 st – 6th editions, Castle Connolly Medical Ltd.
2009 - 2015	Pasadena Magazine Top Doctors
2013 – 2015	SuperDoctors
2011 - 2015	US News and World Report – Top 1% of Surgeons in United States

Extramural Funding(as PI)

City of Hope Cancer Center Seed Grant	7/1/95 - 7/1/98	\$40,000 Direct/Year
NIH R29FIRST Award CA70819	7/1/97 - 7/1/02	\$70,000 Direct/Year
GCRC CReFF Award	2/1/04 – 2/1/05	\$19,970 Direct/Year
NIH R21 Award CA1148890	4/1/05 – 4/1/07	\$225,000 Direct/Year
FAMRI Clinical Innovator Award Number 042275	8/1/05 – 8/1/08	\$108,000 Direct/Year
Susan E. Riley Medical Trust	10/1/06 – 10/1/08	\$80,000 Direct/Year
Phase I Foundation	01/01/09-01/01/11	\$50,000 Direct/Year

Patents

p53-specific T Cell Receptor for Adoptive Immunotherapy. 08/03/2004
 Patent # 6,770,749

Modified vaccinia Ankara expressing p53 in cancer immunotherapy. 08/14/2007
 Patent # 7,256,037

Committees/City Of Hope National Medical Center-Member

(1995-1997) Pharmacy and Therapeutics Committee
 (1995-1999) Medical Records Committee
 (1997-2000) Institutional Review Board
 (1997-2011) Continuing Medical Education Committee
 (1999-2001) Secretary/Treasurer of the Medical Staff – City of Hope
 (2000-2003) Chair, Continuum of Care Committee-City of Hope
 (2003-2012) Chair, Graduate Medical Education Committee
 (2009 - 2012) Faculty Senate Executive Committee

Committees/National/Regional

(1998-2005) Member - National Comprehensive Cancer Network - Head & Neck Guidelines Panel
 (2001-2011) SSO, Training Program Director's Subcommittee - Surgical Oncology
 (2004) Assistant Chair of the Program Committee – Southern California Chapter of the American College of Surgeons
 (2005) Chair, Membership Committee, Los Angeles Surgical Society
 (2003) Ad Hoc Member, NIH Scientific Peer Review Panel – CALGB Cooperative Group
 (2004 - 2005) Member, NIH Scientific Peer Review Panel - NIH Loan Repayment Program
 (2005 - 2009) Member, NIH Scientific Peer Review Panel – Clinical Oncology Study Section
 (2005) Head & Neck Regional Multidisciplinary Advisory Board – CII
 (2006) Chair, Program Committee, Los Angeles Surgical Society
 (2006) Program Chair, Southern California Chapter of the American College of Surgeons Annual Meeting
 (2006) Secretary and President Elect, Los Angeles Surgical Society
 (2007) FAMRI Grant review Committee
 (2007 - 2015) Governor, American College of Surgeons
 (2007 - 2015) Executive Board, Southern California Chapter of the American College of Surgeons
 (2008) President, Los Angeles Surgical Society
 (2008 - 2012) Member - National Comprehensive Cancer Network –Pancreatic CA Guidelines
 (2010 - 2011) Member, NIH Scientific Peer Review Panel – Subcommittee H

Journal Editorial Appointments

Oncology (PRR Inc.)
 Annals of Surgical Oncology

Book Review Section Editor
 Editorial Board 2000 - 2010

Invited Lectures

Baylor University Surgical Society Symposium Advances in the management of rectal cancer The surgeon and hospital as variables in cancer surgery outcomes	June 2000
University of California, San Diego Improving the quality of cancer care in the United States	January 2001
Harbor/UCLA Medical Center Advances in the management of head and neck cancer	February 2004
Immunomolecular Therapeutics Committee – SWOG Poxvirus vaccines for cancer	April 2004
Kern County Medical Center Management of Pancreatic Cancer in 2005	November 2005
University of Arizona – Surgical Grand Rounds Recent Advances in the Management of Rectal Cancer	September 2007
Fountain Valley Regional Medical Center Advances in the Management of Pancreatic Cancer	November 2008
John Wayne Cancer Institute – Surgical Grand Rounds Gastric Cancer Surgery	February 2009
Kern County Medical Center Advances in Gastric Cancer Management	May 2009
LASS/Critical Care Symposium Complications of Pancreatic Surgery	April 2010
Northridge Hospital Medical Center Gastric Cancer Management 2012	March 2012
The Gist of GISTs Los Robles Medical Center	May 2012
Kern County Medical Center Pancreatic Cancer	September 2012
Joint SSO and Japanese Society of Gastroenterological Surgeons Symposium: Updates and Controversies in Gastric Cancer Robotic Versus Laparoscopic Gastrectomy: A Game Changer?	March 2013
John Wayne Cancer Institute – Surgical Grand Rounds Gastric Cancer Update	April 2013

The 68th General Meeting of the Japanese Society of Gastroenterological Surgery GIST Update	July 2013
Cedars-Sinai Medical Center Advances in Gastric Cancer Surgery	April 2014
John Wayne Cancer Institute – Surgical Grand Rounds A Population Based Approach to GIST	September 2014
Cedars-Sinai Medical Center The Gist of GIST	October 2014

Publications

Book Chapters

1. **Ellenhorn JDI**: Contributor to The Mont Reid Handbook. The University of Cincinnati Surgical Manual. Nussbaum MS (ed). Chicago, Year Book Medical Publishers, 1987.
2. **Ellenhorn JDI**: Contributor to The Mont Rein Handbook. The University of Cincinnati Surgical Manual. Hiyama D (ed). Chicago, Year Book Medical Publishers, 1990.
3. Davidson B, **Ellenhorn JDI**, Shah JP: Cancer of the head and neck. In: Textbook of Surgical Oncology. Harvey JC and Beattie E, editors. W.B. Saunders. 1-29, 1995.
4. Coia LR, Bonin SR, Diaz-Canton EA, Pazdur R, **Ellenhorn JDI**: Gastric Cancer. In: Cancer Management: A Multidisciplinary Approach. PRR 87-95, 1996.
5. Coia LR, Bonin SR, Diaz-Canton EA, Pazdur R, **Ellenhorn JDI**: Esophageal cancer. In: Cancer Management: A Multidisciplinary Approach. PRR 96-106, 1996.
6. Bonin SR, Coia LR, Hoff PM, Pazdur R, Diaz-Canton EA, **Ellenhorn JDI**: Esophageal cancer. In: Cancer Management: A Multidisciplinary Approach. PRR 94-103, 1998.
7. **Ellenhorn JDI**, Vassilopoulou-Sellin R, Lustig R: Endocrine Malignancies. In: Cancer Management: A Multidisciplinary Approach. PRR 409-432, 1999.
8. Coia LR, **Ellenhorn JDI**, Ayoub JP: Colorectal and anal cancers. In: Cancer Management: A Multidisciplinary Approach. PRR 273-301, 2000.
9. **Ellenhorn JDI**, Coia LR, Hoff PM, Ayoub JP: Colorectal and anal cancers. In: Cancer Management: A Multidisciplinary Approach. PRR 273-301, 2001.
10. **Ellenhorn JDI**, Coia LR, Alberts SR, Hoff PM: Colorectal and anal cancers. In: Cancer Management: A Multidisciplinary Approach. PRR 295-330, 2002.
11. **Ellenhorn JDI**, Cullinane CA, Coia LR, Alberts SR: Colorectal and anal cancers. In: Cancer Management: A Multidisciplinary Approach. PRR 323-353, 2003.
12. **Ellenhorn JDI**, Cullinane CA, Coia LR, Alberts SR: Colorectal and anal cancers. In: Cancer Management: A Multidisciplinary Approach. PRR 323-357, 2004.
13. **Ellenhorn JDI**, Margolin K: Principles of tumor immunotherapy. In: UICC Manual of Clinical Oncology, 8th edition. John Wiley & Sons 263-284, 2004.
14. **Ellenhorn JDI**, Cullinane CA, Coia LR, Alberts SR: Colorectal and anal cancers. In: Cancer

Management: A Multidisciplinary Approach. PRR 343-375, 2005.

15. Anderson C, **Ellenhorn J**, Pigazzi A. Robotic Gastrectomy with Lymphadenectomy for Gastric Cancer. In: Medical Robotics. I-Tech Education and Publishing 305-314, 2008.

16. **Ellenhorn JDI**. Laparoscopic Subtotal Gastrectomy with Gastrojejunostomy and D2 Lymphadenectomy. In: Minimally Invasive Foregut Surgery for Malignancy. Springer 223-235, 2015.

Abstracts

1. **Ellenhorn JDI**, Hirsch R, Schreiber H, Bluestone JA. In vivo administration of anti-murine CD3-, mAb activates T cells. XII International Congress of the Transplantation Society. Sydney, Australia. August 1988.

2. **Ellenhorn JDI**, Hirsch R, Schreiber H, Bluestone JA. Stimulation of in vivo immune responses using anti-CD3 monoclonal antibodies. 5th Symposium of the German Association of Cancer Research (SEK). Heidelberg, Germany. April 1989.

3. **Ellenhorn JDI**, Schreiber H, Bluestone JA. Anti-tumor immunotherapy with anti-CD3 monoclonal antibodies induces a tumor specific immune response. AAP, ASCI, AACR Annual Meeting. Washington, D.C. May 1989.

4. **Ellenhorn JDI**, Quan SH, Enker WE. Abdominoperineal resection for treatment failure following combined chemotherapy and radiation therapy for anal cancer. Society of Surgical Oncology, 46th Annual Cancer Symposium. March 1993, Los Angeles, CA p.17.

5. **Ellenhorn JDI**, Shah JP, Brennan MF. The impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid. American Association of Endocrine Surgeons. Williamsburg, Virginia. April 1993.

6. **Ellenhorn JDI**, LD Wagman. Survey of physicians attitude towards the field of Surgical Oncology. Society of Surgical Oncology, 46th Annual Cancer Symposium, Boston, Ma. 1995. P117.

7. Curcio L, Chu DZJ, Ahn C, Williams W, Paz B, Riihimaki D, **Ellenhorn JDI**, Wagman L. Local recurrence in breast carcinoma is not an indicator of systemic disease. Society of Surgical Oncology, 46th Annual Cancer Symposium, Boston, Ma. 1995. P28.

8. Chu DZJ, Curcio LD, Ahn C, Williams WL, Paz IB, **Ellenhorn JDI**, Riihimaki DU, Wagman LD. Regional recurrence in breast carcinoma: lymph node involvement. American Radium Society. Paris, France. 1995

9. Paz IB, Wagman LD, **Ellenhorn JDI**, Lorant JA, Andersen JS, Odom-Maryon T. Predictors of outcome of squamous cell cancers (SCC) involving the pharynx and hypopharynx. 41st Annual Meeting of the Society of Head and Neck Surgeons. Boston, MA. 1995.

10. McCarty TM, Owens F, Kuhn JA, Paz IB, **Ellenhorn JDI**, Wagman LD. Squamous cell carcinoma invading the temporal bone. The 4th International Conference on Head and Neck Cancer. Toronto, Canada. 1996.

11. Paz IB, William WL, **Ellenhorn JDI**, Clarke KG, McCarty TM, Odom-Maryon T, Wagman LD. Surgical salvage therapy for local and regional recurrences in squamous cell carcinomas of the head and neck. The 4th International Conference on Head and Neck Cancer. Toronto, Canada. 1996.

12. McCarty TM, **Ellenhorn JDI**, Kuhn JA, Williams WL, Wagman LD. The role of endoscopy in locally advanced thyroid cancer. First World Congress of Surgical Endoscopy. Beijing, China. 1996.

13. **Ellenhorn JDI**, Yu Z, Diamond DJ. The use of transgenic mice to generate p53 specific and HLA restricted Cytolytic T Cells. Thirtieth Annual Meeting of the The Association for Academic Surgery. Chicago, Ill. 1996. P 142.
14. McCarty TM, **Ellenhorn JDI**, Yu Z, Diamond DJ. The use of transgenic mice to generate high affinity p53 specific Cytolytic T Cells. Society of Surgical Oncology, 50th Annual Cancer Symposium, Chicago Ill. 1997. P117.
15. Curcio L, Rupp E, Williams W, Chu DZ, Clarke K, Odom-Maryon T, **Ellenhorn JDI**, Somlo G, Wagman LD. Beyond palliative mastectomy in inflammatory breast cancer - Reassessment of Margin Status. Society of Surgical Oncology, 50th Annual Cancer Symposium, Chicago Ill. 1997. P11.
16. Shaughnessy E, Chu DZJ, ter Veer A, Odom-Maryon T, **Ellenhorn JDI**, Williams W, Paz B, Wagman L. Breast cancer survival in the aged. Society of Surgical Oncology, 50th Annual Cancer Symposium, Chicago Ill. 1997. P12.
17. Chin PL, Paz IB, Clark KG, Odom-Maryon T, Hamasaki V, **Ellenhorn JDI**, Wagman LD. Assessment of complete response to neoadjuvant chemotherapy for head and neck cancer. Society of Surgical Oncology, 50th Annual Cancer Symposium, Chicago Ill. 1997. P96.
18. Curcio LD, Rupp EA, William WL, Chu DZJ, Clarke KG, Odom-Maryon T, **Ellenhorn JDI**, Somlo G, Wagman LD. Beyond palliative mastectomy in inflammatory breast cancer - reassessment of margin status. Society of Surgical Oncology 50th Annual Cancer Symposium. Chicago, IL. 1997.
19. Curcio LD, Paz IB, **Ellenhorn JDI**, Odom-Maryon T, Lorant JA, Moscarello G, Wagman LD. Limb sparing procedures in the treatment of bone sarcoma, have we compromised outcome? Society of Surgical Oncology 50th Annual Cancer Symposium. Chicago, IL. 1997.
20. Shaughnessy EA, Chu DZJ, Ter Veer A, Odom-Maryon T, **Ellenhorn JDI**, Williams WL, Paz IB, Wagman LD. Breast cancer survival in the aged. Society of Surgical Oncology 50th Annual Cancer Symposium. Chicago, IL. 1997.
21. McCarty TM, Williams WL, **Ellenhorn JDI**, Paz IB, Chin PL, Wagman LD. Adenoid cystic carcinoma – salvage therapy for isolated local/regional recurrence. Society of Head and Neck Surgeons. Cancun, Mexico. April 1997.
22. Peralta EA, McCarty TM, Doerr A, Jones PA, Markl I, Diamond DJ, **Ellenhorn JDI**. Immunotherapy of bladder cancer: targeting p53 in a scid mouse model. Society of Surgical Oncology, 51st Annual Cancer Symposium, San Diego, CA. 1998. P 10.
23. McCarty TM, Bebb G, **Ellenhorn JDI**, Wilson T, Stefanacci P, Duhran M, Wagman LD, Paz IB. Pelvic exenteration for recurrent disease: the impact of pelvic sidewall invasion. Society of Surgical Oncology, 51st Annual Cancer Symposium, San Diego, CA. 1998. P 75.
24. Chin PL, Andersen JS, Chu DZJ, Somlo G, Paz IB, **Ellenhorn JDI**. Aesthetic reconstruction following mastectomy for inflammatory breast cancer: is it worthwhile? American Society of Clinical Oncology, Annual Meeting, Los Angeles CA. 1998. 504.
25. Grube B, Chu DZJ, Arber D, Wagman L, Paz IB, **Ellenhorn JDI**. Sentinel node in breast cancer: the dominant node method of localization. American Society of Clinical Oncology, Annual Meeting, Los Angeles CA. 1998. 550.
26. Paz IB, Chin PL, Shibata SI, Vora N, Wagman LD, Chen Y. **Ellenhorn JDI**. Neoadjuvant chemotherapy reduces the need for radical surgery in advanced non-laryngeal head and neck cancer. American Head and Neck Society. Palm Desert, CA. 1999.
27. Doudikian N, Paz IB, Mamelak AN, **Ellenhorn JDI**, Odom-Maryon T, Wagman LD. Is

- surgery indicated for the treatment of invasive squamous and basal cell carcinomas of the cranium and skull base? Society of Surgical Oncology, 52nd Annual Cancer Symposium, Orlando, Fla. 1999.
28. Peralta EA, Liu XP, Diamond DJ, **Ellenhorn JDI**. Transfer of a p53 specific T cell receptor from murine to human T cells. Society of Surgical Oncology, 52nd Annual Cancer Symposium, Orlando, Fla. 1999.
29. Liu XP, Peralta EA, Diamond DL, **Ellenhorn JDI**. Specific recognition of human p53 overexpressing tumor cells by an HLA A2.1-restricted murine T cell receptor expressed in Jurkat T cells. American Association for Cancer Research. 90th Annual Meeting, Philadelphia, Pa 1999.
30. Somlo G, Doroshow J, Chu D, Damon L, **Ellenhorn JDI**, Leong L, Molina A, Margolin K, Scalia M, McNamara M, Schriber J, Reardon D. Tandem cycle high-dose chemotherapy (HDCT) and Peripheral Blood Progenitor Cell Rescue (PBPC) consolidation following neoadjuvant chemotherapy (CT) and modified radical mastectomy (MRM) for Stage IIIB inflammatory breast cancer (IBC). American Society of Clinical Oncology, Annual Meeting, New Orleans, LA. 2000. 550.
31. Blair, S., **Ellenhorn, JDI**. Transanal excision for low rectal cancer curative in early stage disease with favorable histology. Southern California Chapter American College of Surgeons. Huntington Beach, CA January 2000.
32. Lai LL., Mann GN, O'Donnell M, **Ellenhorn JDI**. Outcome after tracheotomy in patients who undergo bone marrow transplantation for hematologic malignancies. Southern California Chapter American College of Surgeons. Huntington Beach, CA January 2000.
33. Somlo G, Doroshow J, Chu D, Damon L, **Ellenhorn J**, Leong L, Molina A, Margolin K, Scalia M, McNamara M, SchriberJ, Reardon D. Tandem cycle high-dose chemotherapy (HDCT) and peripheral blood progenitor cell rescue (PBPC) consolidation following neoadjuvant chemotherapy (CT) and modified radical mastectomy (MRM) for stage IIIB inflammatory breast cancer (IBC). New Orleans, LA. May 2000.
34. Fuller RA, Wagman LD, **Ellenhorn JDI**, Crocitto LE, Wilson TG, Smith SS. Microfluidics detection of cancer with telomerase RNA. 86th Clinical Congress – American College of Surgeons, Surgical Oncology Forum I. Chicago, IL. October 2000.
35. Cullinane CA, Jarrahy R, **Ellenhorn JDI**. Asymptomatic renal neoplasms in the rectal cancer patient. Southern California Chapter American College of Surgeons. Santa Barbara, CA 2001.
36. Cullinane CA, Vora N, **Ellenhorn JD**, Carter N, Shibata S, Wagman LD, Paz IB. Chemotherapy response predicts survival in patients with advanced non-laryngeal squamous cell carcinoma of the head and neck undergoing organ preservation surgery. *Annals of Surgical Oncology*, 9 (1): 83 Suppl. S January 2002.
37. **Ellenhorn JD**, Chu DZ, Wagman LD, Smith DD, Schwarz RE, Paz IB. Paint only is equivalent to scrub and paint for the preoperative preparation of breast and axillary surgery sites. *Annals of Surgical Oncology*, 9(1): 84 Suppl. January 2002.
38. Lamont JP, Faynsod M, Smith D, Pezner R, **Ellenhorn JDI**. Evaluation of routine radiation boost following breast conservation therapy in young patients. American Society of Clinical Oncology. New Orleans, LA. June 2004.
39. Pameijer C, Schultz J, Vora, N, **Ellenhorn JD**, Vora N, Shibata S, Wagman LD, Paz IB. Neoadjuvant chemotherapy in patients with advance non-laryngeal squamous cell carcinoma of

the head and neck permits limited resection. International Conference on Head and Neck Cancer. Washington, DC. August 2004.

40. Faynsod M, Daftarian P, Song GY, Diamond DJ, **Ellenhorn, JD**. Adjuvant activity of CpG ODN and a poxvirus vaccine targeting p53 in a murine colon cancer model. Gastrointestinal Cancers Symposium. San Francisco, CA 2004.

41. Podnos YD, Smith D, Wagman LD, **Ellenhorn JD**. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. Society of Surgical Oncology Cancer Symposium. Atlanta, GA. March 2005.

42. Gibson GR, Daftarian, P, Song G, Diamond DJ, **Ellenhorn JDI**. Synergistic Effect of an Anti-CD25 Antibody on MVAp53 Treated Mice. Society of Surgical Oncology 58th Annual Cancer Symposium, Atlanta, GA March 2005.

43. Song G, Gibson G, Diamond D, **Ellenhorn JDI**. Evaluation of a Poxvirus Vaccine Target Human p53 in a Novel Murine Model. 96th American Associate of Cancer Research Annual Meeting, Anaheim, CA April 2005.

44. Pameijer CRJ, Smith D, McCahill LE, Bimston DN, Wagman LD, **Ellenhorn, JDI**. Full thickness chest wall resection for recurrent breast carcinoma. Southern California Chapter American College of Surgeons. Santa Barbara, CA 2005.

45. Podnos, YD, Smith D, Wagman LD, **Ellenhorn JDI**. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Southern California Chapter American College of Surgeons. Santa Barbara, CA 2005.

46. Pigazzi A, **Ellenhorn JDI**, Paz IB. Robotic-assisted low anterior resection with total mesorectal excision (Video). EAES 2005 International Congress, Venice Lido, June 1-4 2005.

47. Pigazzi A, Ballantyne GH, **Ellenhorn JDI**, Paz IB. Robotic assisted low anterior resection with total mesorectal excision for rectal cancer: report of two cases. EAES 2005 International Congress, Venice Lido, June 1-4 2005.

48. Mojica P, Smith D, **Ellenhorn J**. Adjuvant radiation therapy improves survival for gallbladder adenocarcinoma with regional metastatic disease. Gastrointestinal Cancers Symposium, San Francisco, CA 2006.

49. Song G, Hollstein M, Diamond D, **Ellenhorn J**. Therapeutic effect of a recombinant MVA targeting human p53 in a novel murine model. 97th American Associate of Cancer Research Annual Meeting, Washington DC, April 2006.

50. Guang-Yun Song, Don Diamond, **Joshua Ellenhorn**. Diversity of Immune Response Following Stimulation With an MVA Vaccine Expressing Human p53. 21st International Society for Biological Therapy of Cancer (iSTBc) Annual Meeting, Los Angeles, CA October 2006

51. Pigazzi A, Mojica-Manosa P, Paz IB, Hernandez K, **Ellenhorn JDI**. Impact of recruitment of a trained laparoscopic surgeon on the institutional outcome of laparoscopic colorectal surgery. Society of Surgical Oncology Annual Congress, San Diego, March 23-26, 2006.

52. Pigazzi A, **Ellenhorn JDI**, Paz IB, Outcome of robotic and laparoscopic-assisted total mesorectal excision EAES 2006 International Congress, Berlin, Germany September 13-17, 2006

53. Pigazzi A, Paz IB, **Ellenhorn JD**. Impact of an expert laparoscopic surgeon on the institutional outcomes of laparoscopic colectomy for cancer EAES 2006 International Congress, Berlin, Germany September 13-17, 2006

54. Pigazzi A, DD Smith, **JD Ellenhorn**, IB Paz. Impact of recruitment of a trained laparoscopic surgeon on the institutional outcome of laparoscopic colectomy. Society of

American Gastrointestinal Surgeons (SAGES), Dallas, Texas, April 26-29, 2006 and EAES 2006 International Congress, Berlin, Germany September 13-17, 2006

55. Anderson C, **Ellenhorn J**, Pigazzi A. Pilot series of laparoscopic robotic assisted subtotal gastrectomy with extended lymphadectomy for gastric cancer. Southern California Chapter American College of Surgeons. Santa Barbara, CA 2007.
56. Roberts M, Maghami E, **Ellenhorn JDI**. The role of PET scanning in patients with radioactive iodine scan negative, recurrent thyroid cancer. Southern California Chapter American College of Surgeons. Santa Barbara, CA 2007.
57. Hellan, M, Mojica-Manosa P, **Ellenhorn J**, Kim J. The impact of lymph node number on survival in node-negative pancreatic cancer. GI ASCO Cancer Symposium, Orlando, FL 2007.
58. Anderson C, Hellan M, Kernstine K, **Ellenhorn J**, Trisal V, Pigazzi A. Robotic-assisted minimally invasive surgery for oncologic procedures: a 2 yr experience at a single institution. Society of Surgical Oncology 60th Annual Cancer Symposium, Washington DC March 2007.
59. Song G, Diamond DJ, **Ellenhorn JDI**. Immune Response to an MVA Vaccine Expressing Human p53. Society of Surgical Oncology 60th Annual Cancer Symposium, Washington DC March 2007.
60. Lee B, Qian D, **Ellenhorn JDI**. Gastric Cancer Patients Have Improved Perioperative Outcome When Gastrectomy Is Performed at a High-Volume Center. Society of Surgical Oncology 60th Annual Cancer Symposium, Washington DC March 2007.
61. Hellan M, **Ellenhorn JDI**, Pigazzi A:robotic-assisted surgery for rectal cancer: short-term results of 27 consecutive cases in a cancer center. Pacific Coast Surgical Association, Kohala Coast, Hawaii 2007.
62. Anderson C, Hellan M, Kernstine K, **Ellenhorn J**, Trisal V, Pigazzi A. Robotic-assisted minimally invasive surgery for oncologic procedures: a 2 year experience at a single institution procedure. Society of Surgical Oncology 60th Annual Cancer Symposium, Washington, DC March 14-18, 2007
63. Hellan M, Mojica-Manosa P, Sun C, Bhatia S, Ellenhorn JDI, **Kim J**. Prognostic significance of lymph node number on survival in node-negative pancreatic cancer. Proceedings of American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, 2007.
64. Artinyan A, Hellan M, Mojica P, **Ellenhorn J**, Kim J. Improved survival with radiation therapy in early pancreatic adenocarcinoma. Proceedings of the 43rd Annual Meeting of the American Society of Clinical Oncology, Washington DC, 2007.
65. Tumor Immunology: New Perspectives. An AACR Special conference, Miami, Florida, December 2 – 5 2008. Title “Heterologous Prime-Boost Strategy with Listeria and MVA: Enhanced Immunogenicity but Increase MDSC population”
66. Artinyan A, Soriano P, Low T, **Ellenhorn JDI**, Kim J. Tumor location determines survival in pancreatic cancer. Proceedings of the 2008 American Hepato Pancreato Biliary Association Annual Meeting, Fort Lauderdale, FL.
67. Artinyan A, Kim J, Soriano P, Ellenhorn JDI. Survival from metastatic gastrointestinal stromal tumors in the era of imatinib. *Ann Surg Oncol* 15(S2):92, 2008.
68. Artinyan A, Kim J, Soriano P, Bhatia S, **Ellenhorn JDI**. Socioeconomic disparities in patients with metastatic gastrointestinal stromal tumors: imatinib and the shift toward equality. Proceedings of American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, FL, 2008.

69. Artinyan A, Soriano PA, **Ellenhorn JD**, Kim J. Ethnic differences in outcome from resected gastric adenocarcinoma in the United States: Improved survival in Asian Americans. Proceedings of 2008 ASCO Annual Meeting, Chicago, IL.
70. 24th Annual Meeting of the International Society for Biological Therapy of Cancer (WashingtonDC) Enhancement of a p53-based cancer vaccine by heterologous prime/boost immunization and Toll-like receptors stimulation 2009
71. Mailey BA, Sun C, Artinyan A, Prendergast C, Pigazzi A, **Ellenhorn J**, Bhatia S, **Kim J**. Asian-Americans have superior outcomes for gastric adenocarcinoma. Proceedings of the ASCO Gastrointestinal Cancer Symposium, San Francisco, CA, 2009.
72. Guzman EA, Pigazzi A, Lee B, Kim J, **Ellenhorn JD**. Totally laparoscopic gastric resection with extended lymphadenectomy for adenocarcinoma of the stomach. *Ann Surg Oncol* 16(S1):5, 2009.
73. Mckenzie S, Artinyan A, Mailey B, Pigazzi A, **Ellenhorn JDI**, Kim J. Surgical Resection Is the Only Effective Therapy for Primary and Metastatic Pancreatic Islet Cell Carcinoma. 51st Annual Meeting, Society for Surgery of the Alimentary Tract New Orleans, Louisiana 2010
74. Kachikwu EL, Trisal V, Kim J, Pigazzi A, **Ellenhorn JDI**. Double-Stapled Technique for the Esophageal Anastomosis: a New Paradigm. 51st Annual Meeting, Society for Surgery of the Alimentary Tract New Orleans, Louisiana 2010
75. Holt A, Duan L, Henderson K, Bernstein L, Ta J, **Ellenhorn J**, Kruper L. Disparities in Reconstruction Rates after Mastectomy. Society of Surgical Oncology 63rd SSO Annual Cancer Symposium. St. Louis, Missouri 2010
76. Artinyan A, Anaya D, Mailey B, **Ellenhorn JDI**. Neoadjuvant Chemotherapy is Superior to Adjuvant Treatment in Resectable Pancreatic Adenocarcinoma, Society of Surgical Oncology 63rd SSO Annual Cancer Symposium. St. Louis, Missouri 2010
77. Ojo J, McKenzie S, Morgan R, Paz IB, Leong L, **Ellenhorn J**, GarciaAguilar J, Lai L. Cytoreductive Surgery and Intraperitoneal Chemotherapy Improve Survival in Patients with Peritoneal Carcinomatosis from Colorectal Cancer. Society of Surgical Oncology 63rd SSO Annual Cancer Symposium. St. Louis, Missouri 2010
78. **Ellenhorn JDI**. Laparoscopic and Robotic Distal Gastrectomy with Lymphadenectomy for Gastric Adenocarcinoma in an Obese Patient. 52nd Annual Meeting, Society for Surgery of the Alimentary Tract, Chicago, Illinois 2011
79. Ho J, Kachikwu EL, Trisal V, Kim J, Pigazzi A, **Ellenhorn JDI**. Minimally Invasive Gastrectomy for Gastric Cancer: a Single Institution Experience. 52nd Annual Meeting, Society for Surgery of the Alimentary Tract, Chicago, Illinois 2011
80. Senthil M, Behrendt C, Gonser L, **Ellenhorn J**, Kounalakis N, Mckenzie S, Vora L, Yim JH. Utility of preoperative magnetic resonance imaging in breast cancer. Society of Surgical Oncology 64th SSO Annual Cancer Symposium. San Antonio, Texas 2011
81. Ho J, Kachikwu E, Nelson R, Pigazzi A, **Ellenhorn J**. Laparoscopic Distal Gastrectomy for Gastric Cancer: Institutional Experience with 38 Consecutive Patients and Oncologic Outcomes. Society of Surgical Oncology 64th SSO Annual Cancer Symposium. San Antonio, Texas 2011
82. Le MN, Ellenhorn J, Kim J, Trisal V, **Ellenhorn JDI**. Quality of life following laparoscopic distal gastrectomy with modified billroth II reconstruction. 2012 Gastrointestinal Cancers Symposium. San Francisco, California 2012.
82. O'Connor V, Deutsch GB, Arena EA, Albright J, O'Connor RP, Sim M, Bilchik A. **Ellenhorn JDI**. A Decade of Experience with Postoperative Imatinib Mesylate for Gastrointestinal Stromal Tumors: Does the Duration of Treatment Increase Long-term Survival?

Society of Surgical Oncology 67th SSO Annual Cancer Symposium. Phoenix, Arizona 2014

Letters to the Editor/Invited Editorials

1. Ellenhorn MJ, Oles DP, Smith SJ, Adler R, Ellenhorn NL, **Ellenhorn JDI**, Ben-Ezra J, Roth RH, Schwartz JL, Weinstock S. On the physical death of Jesus Christ. JAMA May 255:2754-2755, 1986.
2. Chu DZ, **Ellenhorn JDI**, Paz IB, Wagman LD, Williams WL Jr. CEA for monitoring colon cancer. JAMA Feb 271:345-346, 1994.
3. Schwarz RE, **Ellenhorn JDI**. Influence of hospital volume on mortality following major cancer surgery [letter]. JAMA Apr 281:1374-1375, 1999.
4. **Ellenhorn JDI** and Gaal K K. Editorial: DNA fingerprinting and breast cancer. Ann.Surg.Oncol., 11: 551-552, 2004.
5. **Ellenhorn JDI**. A Review of: "Gastrointestinal Cancer". Cancer Investigation. 24:545 2006.
6. Artinyan A, **Ellenhorn J**. The appropriate selection of a representative sample population: the case of surveillance, epidemiology, and end results and gastrointestinal stromal tumor. Cancer Epidemiol Biomarkers Prev. 18:1014-5, 2009.
7. **Ellenhorn JDI**. When it comes to the efficacy of metastasectomy, biology is king. Oncology (Williston Park). 27:1051, 2013.

Journal Articles

1. **Ellenhorn JDI**, Hirsch R, Schreiber H, Bluestone JA: In vivo administration of anti-CD3 prevents malignant progressor tumor growth. *SCIENCE* 242:569-571, 1988.
2. **Ellenhorn JDI**, Hirsch R, Hartley J, Bluestone JA: Dose dependent activation of murine T cells following in vivo administration of anti-murine CD3. *Transplantation Proceedings* 21:1:1013-1014, 1989.
3. Hirsch R, **Ellenhorn JDI**, Bluestone JA: In vivo administration of anti-CD3 monoclonal antibody can activate immune responses thus preventing malignant tumor growth. *International Symposium of the Princess Takamatsu Cancer Research Fund* 19:237, 1988.
4. **Ellenhorn JDI**, Schreiber H, Bluestone JA: Mechanism of tumor rejection by anti-CD3 monoclonal antibody treated mice. *J Immunol* 144:2840-2846, 1990.
5. **Ellenhorn JDI**, Woodle ES, Gobreal I, Thistlethwaite JR, Bluestone JA: Activation of human T cells in vivo following treatment of transplant recipients with OKT3. *Transplantation* 50:608-612, 1990.
6. **Ellenhorn JDI**, Fowl R, Akers D, Kempczinski RF: Femur fracture with limb shortening causing polytetrafluoroethylene femoral popliteal graft occlusion. *J Vasc Surgery* 12:558-560, 1990.
7. Kast WM, Bluestone JA, Heemekerck MHM, Spaargaren J, Voordouw AC, **Ellenhorn JDI**, Melief CJM: Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells. *J Immunol* 145:2254-2259, 1990.
8. **Ellenhorn JDI**, Woodle ES, Thistlethwaite JR, Bluestone JA: T lymphocyte activation following OKT3 treatment. *Current Surgery* 47:458-459, 1990.
9. Newell K, **Ellenhorn JDI**, Bruce D, Bluestone JA: In vivo T cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. *Proc Nat Acad Sci USA* 88:1074-1078, 1991.
10. Newell KA, **Ellenhorn JDI**, Hirsch R, Bluestone JA: Immunopotential of anti-viral and anti-tumor immune responses using anti-T cell receptor antibodies and mitogens. *Ann N Y Acad Sci* 636:279, 1991.
11. **Ellenhorn JDI**, Turnbull ADM: Mature cystic teratoma of the ovary. *Surgical Rounds* 16:387, 1993.
12. **Ellenhorn JDI**, LaQuaglia MP, Geer RJ: Exposure of the mucosa of the gastroesophageal junction in patients with Mallory-Weiss tears. *Surg Gynecol Obstet* 177:91-92, 1993.
13. **Ellenhorn JDI**, Lambroza A, Lindsley KL, LaQuaglia MP: Treatment-related esophageal stricture in pediatric patients with cancer. *Cancer* 71:4084-4090, 1993.
14. **Ellenhorn JDI**, Shah JP, Brennan MF: The impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid. *Surgery* 114:1078-1082, 1993.
15. **Ellenhorn JDI**, Enker WE: Salvage abdominoperineal resection following combined chemotherapy and radiation therapy for epidermoid carcinoma of the anus. *Ann Surg Oncol* 1:105-110, 1994.
16. **Ellenhorn JDI**, Wagman LD: Survey of physician attitude towards the field of surgical oncology. *Ann Surg Oncol*. 3:406-410 1996.
17. **Ellenhorn JDI**, Yu Z, Diamond DJ. Generation of p53 specific and HLA restricted cytolytic T lymphocytes using recombinant vaccinia virus and HLA transgenic mice. Owen H. Wangenstein *Surgical Forum* Volume XLVII 503-505, 1996.
18. Cohen JS, O'Donnell MR, **Ellenhorn JDI**: Management of perianal infections following bone marrow transplantation. *Dis Col Rectum*, 39:981-985 1996.

19. McCarty TM, Liu X, Schwarz RE, Diamond DJ, **Ellenhorn JDI**. Targeting p53 for adoptive T cell immunotherapy. Owen H. Wangenstein Surgical Forum Volume XLVIII 783-785, 1997.
19. Curcio LD, Chu DZL, Ahn C, Williams WL, Paz IB, Riihimaki D, **Ellenhorn JDI**, and Wagman L: Local recurrence in breast cancer: Implications for systemic disease. *Ann Surg Oncol*.4:24-27 1997.
21. Yu Z, Liu X, McCarty TM, Diamond DJ, **Ellenhorn JDI**: The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. *Journal of Surgical Research*, 69:337-343 1997.
22. McCarty TM, Kuhn JA, Williams WL, **Ellenhorn JDI**, O'Brien JC, Preskitt JT, Leiberman ZH, Stephens J, Clarke K, Odom-Maryon T, Wagman LD: Surgical management of thyroid cancer invading the airway. *Annals of Surgical Oncology*, 4:403-408 1997.
23. McCarty TM, Yu Z, Liu X, Diamond DJ, **Ellenhorn JDI**: An HLA Restricted p53 Specific Immune Response from p53 Knockout Transgenic Mice. *Annals of Surgical Oncology*, 5:93-99 1998.
24. McCartyTM, Liu XP, Sun J, Peralta EA, Diamond DJ, and **Ellenhorn JDI**: Targeting p53 for Adoptive T-Cell Immunotherapy. *Cancer Research*, 58:2601-2605 1998.
25. Curcio LD, Rupp E, Williams WL, Chu DZJ, Clarke CK, Odom-Maryon T, **Ellenhorn JDI**, Somlo G, and Wagman LD: Beyond palliative mastectomy in inflammatory breast cancer – a reassessment of margin status. *Annals of Surgical Oncology*, 6:249-254 1999.
26. Schwarz RE, McCarty TM, Peralta EA, Diamond DL, **Ellenhorn JDI**: An orthotopic in vivo model of human pancreatic cancer. *Surgery*, 126:562-567 1999.
27. Schwarz RE, Keny H, **Ellenhorn JDI**: A mortality-free decade of pancreatoduodenectomy: is quality independent of quantity? *The American Surgeon*, 65:949-954 1999.
28. Peralta EA, Liu XP McCartyTM, Wilson TG, Diamond DJ, and **Ellenhorn JDI**: Immunotherapy of bladder cancer targeting p53. *Journal of Urology*, 162:1806-1811 1999.
29. Liu XP, Peralta EA, **Ellenhorn JDI**, Diamond DL: Targeting of Human p53-overexpressing Tumor Cells by an HLA A*0201-restricted murine t-cell receptor expressed in Jurkat t cells. *Cancer Research*, 60: 693-701 2000.
30. Chin, PL, Andersen JS, Chu DZJ, Somlo G, Paz IB, **Ellenhorn JDI**: Aesthetic reconstruction following mastectomy for inflammatory breast cancer: is it worthwhile? *Journal of the American College of Surgeons*, 190: 304-309 2000.
31. Blair S, **Ellenhorn JDI**: Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology. *The American Surgeon*, 66:817-820 2000.
32. Peralta EA, **Ellenhorn JDI**, Wagman LD, Daxis A, Andersen JS, Chu DZ: Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. *The American Journal of Surgery*, 180:439-445 2000.
33. Pfister DG, Ang K, Brockstein B, Colevas AD, **Ellenhorn JDI**, Goepfert H, Hicks WL, Hong WK, Kies MS, Lydiatt W, McCaffrey T, Mittal BB, Ridge JA, Schuller DE, Shah JP, Spencer S, Trotti A, Urba S, Weymuller EA, Wheeler RH, Wolf GT: NCCN Practice Guidelines for Head and Neck Cancers. *Oncology (Huntingt)*, 14:163-94 2000.
34. Fuller RA, Wagman LD, **Ellenhorn JDI**, Crocitto LE, Wilson TG, Smith SS: Microfluidics detection of cancer with telomerase RNA. *Journal of the American College of Surgeons*, 191: Supplement 1, S17 2000.
35. Cullinane C, Jarrahy R, Wilson T, **Ellenhorn JDI**: Asymptomatic renal neoplasms in the rectal cancer patient. *The American Surgeon*, 67:1162-1164 2001.

36. Pezner RD, Chu DZJ, **Ellenhorn JDI**: Intraoperative radiation therapy for patients with recurrent rectal and sigmoid cancer in previously irradiated fields. *Radiotherapy and Oncology*, 64:47-52 2002.
37. Epel M, **Ellenhorn JDI**, Diamond DJ, Reiter Y: A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. *Cancer Immunol Immunother*, 51:565-573 2002.
38. Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, **Ellenhorn JDI**: CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an murine established tumor model. *The Journal of Immunology* 170:3401-3407 2003.
39. Cullinane CA, **Ellenhorn JDI**, Weitzel JN: Microsatellite instability is a rare finding in tumors of patients with both primary renal and rectal neoplasms. *Cancer Genet Cytogenet*, 148:163-165 2004.
40. Wang Z, La Rosa C, Mekhouba, S, Lacey SF, Villacres MC, Markel S, Longmate J, **Ellenhorn JD**, Siliciano RF, Buck C, Britt WJ, and Diamond DJ. Attenuated Poxviruses Generate Clinically Relevant Frequencies of CMV-Specific T cells. *Blood*, 104:847-56 2004.
41. Daftarian P, Ali S, Song G, Faynsod M, Longmate J, Diamond DJ, **Ellenhorn JDI**. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. *Cancer Research*. 64:5407-5414 2004.
42. Podnos YD, Smith D, Wagman LD, **Ellenhorn JDI**. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. *The American Surgeon*, 71:731-734 2005.
43. Pameijer CRJ, Smith D, McCahill LE, Bimston DN, Wagman LD, **Ellenhorn JDI**. Full-thickness chest wall resection for recurrent breast carcinoma: an institutional review and meta-analysis. *The American Surgeon*, 71:711-715 2005.
44. **Ellenhorn JDI**, Smith D, Schwarz RE, Kawachi MH, Wilson TG, McGonigle KF, Wagman LD, IB Paz. Paint-only is equivalent to scrub-and-paint in preoperative preparation of abdominal surgery sites. *Journal of the American College of Surgeons*, 201:737-741, 2005.
45. Podnos YD, Smith D, Wagman LD, **Ellenhorn JDI**: Radioactive iodine offers survival improvement in patients with follicular carcinoma of the thyroid. *Surgery*, 138:1072-1077, 2005.
46. Pigazzi A, **Ellenhorn JDI**, Ballantyne GH, Paz IB: Robotic-assisted laparoscopic low anterior resection with total mesorectal excision for rectal cancer. *Surgical Endoscopy*, 20:1521-1525 2006.
47. Podnos YD, Tsai NC, Smith D, **Ellenhorn JDI**: Factors affecting survival in patients with anal melanoma. *The American Surgeon* 72:917-920 2006.
48. Mojica-Manosa P, Smith D, **Ellenhorn JDI**: Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. *Journal of Clinical Oncology*, 25:1043-1047, 2007.
49. Podnos YD, Smith DD, Wagman LD, **Ellenhorn JDI**. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. *J Surg Oncol*. 96:3-7 2007.
50. Mojica P, Smith D, **Ellenhorn JDI**. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. *J Surg Oncol*. 96:8-13 2007.
51. Anderson C, **Ellenhorn JDI**, Hellan M, Pigazzi A. Pilot series of robot-assisted laparoscopic subtotal gastrectomy with extended lymphadenectomy for gastric cancer. *Surgical Endoscopy* 21:1662-1666 2007.

52. Hellan M, Anderson C, **Ellenhorn JDI**, Paz B, Pigazzi A. Short-Term Outcomes After Robotic-Assisted Total Mesorectal Excision for Rectal Cancer. *Ann Surg Oncol.* 14:3168-3173 2007.
53. Song GY, Gibson G, Haq W, Huang ECC, Srivasta T, Hollstein M, Daftarian P, Wang Z, Diamond D, **Ellenhorn JDI**. An MVA vaccine overcomes tolerance to human p53 in mice and humans. *Clinical Immunology and Immunotherapy* 56:1193-205 2007.
54. Roberts M, Maghami E, Kandeel F, Yamauchi D, Ellenhorn HL, Ellenhorn JDI. The role of positron emission tomography scanning in patients with radioactive iodine scan-negative, recurrent differentiated thyroid cancer. *Am Surg.* 73:1052-1056 2007.
55. Lowe TE, **Ellenhorn JDI**, Wong C, Somlo G. Increased abdominal girth in a 29-year-old breast cancer patient with extensive liver metastasis and presumed chemotherapy induced amenorrhea. A case report and review of the literature. *Breast Cancer Research and Treatment* 106:305-306 2007.
56. Anderson C, Hellan M, Kernstine K, **Ellenhorn JDI**, Lai L, Trisal V, Pigazzi A. Robotic surgery for gastrointestinal malignancies. *Int J Med Robot.* 3:297-300 2007.
57. Pigazzi A, Anderson C, Mojica-Manosa P, Smith D, Hernandez K, Paz IB, **Ellenhorn JDI**. Impact of a full-time preceptor on the institutional outcome of laparoscopic colectomy. *Surg Endosc.* 22:635-639 2008.
58. Artinyan A, Hellan M, Mojica-Manosa P, Chen YJ, Pezner R, **Ellenhorn JDI**, Kim J. Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: a United States population-based assessment. *Cancer* 112:34-42 2008.
59. Hellan M, Sun CL, Artinyan A, Mojica-Manosa P, Bhatia S, **Ellenhorn JD**, Kim J. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. *Pancreas.* 37:19-24 2008.
60. Artinyan A, Soriano PA, Prendergast C, Low T, **Ellenhorn JD**, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. *HPB (Oxford).* 10:371-376 2008.
61. Shen J, **Ellenhorn J**, Qian D, Kulber D, Aronowitz J. Skin-sparing mastectomy: a survey based approach to defining standard of care. *Am Surg.* Oct;74:902-905 2008.
62. Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, **Ellenhorn JD**. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. *Cancer Epidemiol Biomarkers Prev.* 17:2194-2201 2008.
63. Jo S, Juhasz A, Zhang K, Ruel C, Loera S, Wilczynski SP, Yen Y, Liu X, **Ellenhorn J**, Lim D, Paz B, Somlo G, Vora N, Shibata S. Human Papillomavirus Infection as a Prognostic Factor in Oropharyngeal Squamous Cell Carcinomas Treated in a Prospective Phase II Clinical Trial. *Anticancer Research.* 29:1467-1474 2009.
64. Guzman EA, Pigazzi A, Lee B, Soriano PA, Nelson RA, Benjamin Paz I, Trisal V, Kim J, **Ellenhorn JD**. Totally laparoscopic gastric resection with extended lymphadenectomy for gastric adenocarcinoma. *Ann Surg Oncol* 16:2218-2223 2009.
65. Guzman EA, Nelson RA, Kim J, Pigazzi A, Trisal V, Paz B, **Ellenhorn JDI**. Increased incidence of pancreatic fistulas after the introduction of a bioabsorbable staple line reinforcement in distal pancreatic resections. *Am Surg.* 75:954-957 2009.
66. Kim J, Sun CL, Mailey B, Prendergast C, Artinyan A, Bhatia S, Pigazzi A, **Ellenhorn JDI**. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. *Ann Oncol.* 21:152-60 2010.

67. McKenzie S, Mailey B, Artinyan A, Kim J, **Ellenhorn JDI**. The incidence and outcomes of pancreatectomy in patients with metastatic pancreatic adenocarcinoma. *JOP*. 11:341-347 2010.
68. Shen X, Mailey B, **Ellenhorn JD**, Chu PG, Lowy AM, Kim J. CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. *J Gastrointest Surg*. 13:1955-1962 2009.
69. Ishizaki H, Song G-Y, Srivastava T, Driscoll Carroll K, Shahabi V, Diamond DJ and **Ellenhorn JDI**. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. *J of Immunotherapy* 33:609-617 2010.
70. McKenzie S, Lee W, Artinyan A, Mailey B, Pigazzi A, **Ellenhorn JDI**, Kim J. Surgical Resection and Multidisciplinary Care for Primary and Metastatic Pancreatic Islet Cell Carcinomas. *J Gastrointest Surg*. 11:341-347 2010
71. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, **Ellenhorn JD**, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic Cancer. *J Natl Compr Canc Netw*. 8:972-1017 2010
72. Sorrell AD, Lee S, Stolle C, **Ellenhorn JDI**, Grix A, Kaelin WG Jr, Weitzel JN. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma. *Clin Genet*. 79:639-45 2011.
73. Minimally Invasive Total Gastrectomy for Gastric Cancer: A Pilot Series. Kachikwu EL, Trisal V, Kim J, Pigazzi A, **Ellenhorn JD**. *J Gastrointest Surg*. 15:81-86 2011.
74. Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, **Ellenhorn JD**. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. *Cancer Immunol Immunother*. 60:99-109 2011.
75. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Artinyan A, Anaya DA, McKenzie S, **Ellenhorn JD**, Kim J. *Cancer* 117:2044-2049 2011.
76. Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ishizaki H, **Ellenhorn JD**, Hensel M, Metelitsa L, Diamond DJ. Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-Targeting Salmonella-Based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors. *Cancer Res*. 71:4183-91 2011.
77. McKenzie S, Artinyan A, Holt AD, Garcia-Aguilar J, **Ellenhorn J**, Morgan R, Paz B. Selection criteria for complete cytoreduction after cytoreductive surgery for peritoneal surface malignancy: lessons learned from our first series of patients. *Am Surg*. 77:430-7 2011.
78. Kruper L, Holt A, Xu XX, Duan L, Henderson K, Bernstein L, **Ellenhorn J**. Disparities in Reconstruction Rates After Mastectomy: Patterns of Care and Factors Associated with the Use of Breast Reconstruction in Southern California. *Ann Surg Oncol*. 18:2158-2165 2011.
79. Song GY, Srivastava T, Ishizaki H, Lacey S, Diamond D, **Ellenhorn J** Recombinant modified vaccinia virus Ankara (MVA) expressing wild type human p53 induces specific antitumor CTL expansion *Cancer Investigation* 29:501-510, 2011.
80. Manuel ER, Blache CA, **Ellenhorn JD**, Diamond DJ. Survivin the battle against immunosuppression. *Oncoimmunology*. 1:240-241 2012.
81. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, **Ellenhorn JD**, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong

- A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, Version 2.2012: Featured Updates to the NCCN Guidelines. *J Natl Compr Canc Netw.* 10:703-713 2012.
82. Oxner CR, Vora L, Yim J, Kruper L, **Ellenhorn JD**. Magnetic resonance imaging-guided breast biopsy in lesions not visualized by mammogram or ultrasound. *American Surgeon* 2012 78:1087-1090 2012.
- 83 Arrington AK, Nelson R, Chen SL, **Ellenhorn JD**, Garcia-Aguilar J, Kim J. The Evolution of Surgical Technique for Total Gastrectomy Over a 12-Year Period: A Single Institution's Experience. *American Surgeon* 2012 78:1054-1058 2012.
84. Blache CA, Manuel ER, Kaltcheva TI, Wong AN, **Ellenhorn JD**, Blazar BR, Diamond DJ. Systemic Delivery of Salmonella Typhimurium Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. *Cancer Res.* 72:6447-6456 2012.
85. Aronowitz JA, **Ellenhorn JD**. Adipose Stromal Vascular Fraction Isolation: A Head-to-Head Comparison of Four Commercial Cell Separation Systems. *Plast Reconstr Surg.* 132:932-939 2013.
86. Behrendt CE, Tumyan L, Gonser L, Shaw SL, Vora L, Paz IB, **Ellenhorn JD**, Yim JH. Evaluation of expert criteria for preoperative magnetic resonance imaging of newly diagnosed breast cancer. *Breast.* 23:341-5 2014
87. Hardwick NR, Carroll M, Kaltcheva TI, Qian D4, Lim D, Leong L, Chu P, Kim J, Joseph C, Fakhri MG, Yen Y, Espenschied J, **Ellenhorn JD**, Diamond DJ, Chung V. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T cell responses. *Clin Cancer Res.* 20:4459-4470 2014.
88. Hardwick N, Chung V, Cristea M, Ellenhorn JD, Diamond DJ. Overcoming immunosuppression to enhance a p53MVA vaccine. *Oncoimmunology.* 15:e958949 2014.

Presentations at National Meetings

In vivo administration of anti-murine CD3-, mAb activates T cells. XII International Congress of the Transplantation Society. Sydney, Australia. August 1988.

Stimulation of in vivo immune responses using anti-CD3 monoclonal antibodies. 5th Symposium of the German Association of Cancer Research (SEK). Heidelberg, Germany. April 1989.

Anti-tumor immunotherapy with anti-CD3 monoclonal antibodies induces a tumor specific immune response. AAP, ASCI, AACR Annual Meeting. Washington, D.C. May 1989.

Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Society of University Surgeons. Los Angeles, California. February 1990

Salvage abdominoperineal resection following combined chemotherapy and radiation therapy for epidermoid carcinoma of the anus. Society of Surgical Oncology. Los Angeles, California. March 1993.

The impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid. American Association of Endocrine Surgeons. Williamsburg, Virginia. April 1993.

Survey of physician attitude towards the field of surgical oncology. Society of Surgical Oncology 48th Annual Cancer Symposium. Boston, Massachusetts. March 1994.

Generation of p53 specific and HLA restricted cytolytic T lymphocytes using recombinant vaccinia virus and HLA transgenic mice. Owen H. Wangenstein Surgical Forum. San Francisco, California. October 1996.

The use of transgenic mice to generate p53 specific and HLA restricted Cytolytic T cells (CTL). The Association for Academic Surgery. Chicago Illinois. November 1996.

Laparoscopic and Robotic Total Gastrectomy with D2 Lymphadenectomy and OrVil Esophagojejunostomy. American College of Surgeons Clinical Congress. Chicago Illinois October 2009.

Laparoscopic and Robotic Total Gastrectomy with D2 Lymphadenectomy and OrVil Esophagojejunostomy. American College of Surgeons Clinical Congress. Washington DC October 2010.

Laparoscopic and Robotic Distal Gastrectomy with Lymphadenectomy for Gastric Adenocarcinoma in an Obese Patient. Plenary Session. 52nd Annual Meeting, Society for Surgery of the Alimentary Tract, Chicago Illinois May 2011.

Robotic Versus Laparoscopic Gastrectomy: A Game Changer? Plenary Session. 66th Annual Meeting, Society of Surgical Oncology, Washington, D.C. March 2013.